New Blood Test Can Detect 50 Different Types Of Cancer

Results from a trial conducted by the UK National Health Service have shown promise for a new blood test that can detect over 50 types of cancer. This test has the potential to expedite cancer diagnosis and streamline patient treatment, as reported by the BBC. Out of 5,000 individuals exhibiting suspected cancer symptoms, the test accurately identified two-thirds of the cancers. 

Furthermore, in 85% of these positive cases, it successfully identified the primary site of the cancer. The test is particularly effective at detecting hard-to-detect cancers such as head and neck, bowel, lung, pancreatic, and throat cancers, according to the findings presented at the American Society of Clinical Oncology's annual meeting in Chicago. 

Developed by Grail, a US-based company, the test, known as the Galleri test, aims to detect cancer signals and predict the origin of the cancer to guide diagnostic evaluations. By identifying specific changes in genetic code fragments released by various cancers, the test has the potential to detect treatable cancers early, thereby saving lives. 

Also read: HMPV Respiratory Virus: Know Symptoms, And Precautionary Measures

While the test is not precise enough to definitively confirm or rule out the presence of cancer, lead researcher Prof Mark Middleton stated that it is highly valuable for patients. He explained that the test was 85% accurate in identifying the source of the cancer, which can be immensely helpful since the appropriate diagnostic test is often not immediately apparent when a patient presents with symptoms. 

This prediction from the test enables healthcare professionals to determine whether a scope or a scan is necessary, ensuring that the most appropriate test is conducted from the outset. While the study's findings suggest that this test could support general practitioners in making clinical assessments, further extensive research through larger trials is required to assess its potential for improving GP assessments and ultimately enhancing patient outcomes.